{"ticker": {"uuid": "ed225238-5523-4d1f-bb4d-bfcdc7607388", "symbol": "VVY", "name": "Vivoryon Therapeutics N.V.", "exchange": "AMS", "country": "NL", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Kidney drug developer Vivoryon lines up June 11 Q1 2026 results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNdjl5NU04OXJjRUQtWEZ5RUdZQ3hPek5nN1hnNTVrbE1yajhWQzc0UjZwVUIzc1RhUnJVazhnVzVxXzVraFh3Tmptd3ZuN0p2RXlFOXdSSXdZSlgtVEJMSGlSbEs2UTJ3cWtnVHpMMGc0c1REUElHbjRhbm5FVmxKR2Ywd3NLbDZQUEM0bmxGXzA2ZlAyQTVuMzNYdGM2aHYyd1Y0UVdiRWQ4NkM0Snhfci1kdG84ejBHOWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOQTlIMlR2QTBiWGNGTzRucE5NMFAyLUsyalNOX1U2ZldKVnhuRVlCdmVpdkVsa1RmVjFKUTdsb085ZEJEY0p0M2dHOGhvQU12d2dwSHh2MHFjV3dfM0drdmlQbWY1a2RVSzRpNlF3U0djTldqSllQTnk2bWFna3RYd2Vjbzh0T2lqRVEyMFZweTRfV3UyQ1luVlVUa2kxdw?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivoryon Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE9WelV5WDB5SE11ZWZGWUdLNklpNldDa0s3b3JfUWR0UXRabTN2U0VUUVY5ZnVxUHpjY0YzWVA1dEpBV2Y5X2g2eXNvNVI0RjBlOVByLXhQSHozTEZNaC1UQS1sVWZwRzdiN2NrcFVpRy0xM0VnSGc?oc=5", "source_name": "The Pharma Letter", "published_at": "2024-06-27T23:52:12+00:00", "published_display": "27 Jun 2024 23:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivoryon Therapeutics N.v Stock Price Forecast. Should You Buy VVY.AS?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiS0FVX3lxTE1MOE5hemZvVXR5RTlqekhzUUxFNEUwbnl2bEItckQwWHFuQVRfcmdpRVlOTHVhY0xGYkRiYnNVekJSeUs1UHJ2OGk3bw?oc=5", "source_name": "StockInvest.us", "published_at": "2021-05-27T13:32:20+00:00", "published_display": "27 May 2021 13:32", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Kidney drug developer Vivoryon lines up June 11 Q1 2026 results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNdjl5NU04OXJjRUQtWEZ5RUdZQ3hPek5nN1hnNTVrbE1yajhWQzc0UjZwVUIzc1RhUnJVazhnVzVxXzVraFh3Tmptd3ZuN0p2RXlFOXdSSXdZSlgtVEJMSGlSbEs2UTJ3cWtnVHpMMGc0c1REUElHbjRhbm5FVmxKR2Ywd3NLbDZQUEM0bmxGXzA2ZlAyQTVuMzNYdGM2aHYyd1Y0UVdiRWQ4NkM0Snhfci1kdG84ejBHOWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOQTlIMlR2QTBiWGNGTzRucE5NMFAyLUsyalNOX1U2ZldKVnhuRVlCdmVpdkVsa1RmVjFKUTdsb085ZEJEY0p0M2dHOGhvQU12d2dwSHh2MHFjV3dfM0drdmlQbWY1a2RVSzRpNlF3U0djTldqSllQTnk2bWFna3RYd2Vjbzh0T2lqRVEyMFZweTRfV3UyQ1luVlVUa2kxdw?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivoryon Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE9WelV5WDB5SE11ZWZGWUdLNklpNldDa0s3b3JfUWR0UXRabTN2U0VUUVY5ZnVxUHpjY0YzWVA1dEpBV2Y5X2g2eXNvNVI0RjBlOVByLXhQSHozTEZNaC1UQS1sVWZwRzdiN2NrcFVpRy0xM0VnSGc?oc=5", "source_name": "The Pharma Letter", "published_at": "2024-06-27T23:52:12+00:00", "published_display": "27 Jun 2024 23:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivoryon Therapeutics N.v Stock Price Forecast. Should You Buy VVY.AS?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiS0FVX3lxTE1MOE5hemZvVXR5RTlqekhzUUxFNEUwbnl2bEItckQwWHFuQVRfcmdpRVlOTHVhY0xGYkRiYnNVekJSeUs1UHJ2OGk3bw?oc=5", "source_name": "StockInvest.us", "published_at": "2021-05-27T13:32:20+00:00", "published_display": "27 May 2021 13:32", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 62, "total_relevant": 4, "sentiment_summary": {"positive": 1, "negative": 0, "neutral": 3, "score": 54, "total": 4, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 54, "events": [{"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "general", "label": "Market update", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 1, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 1.4, "latest_week": "2026-07-10", "one_week_move": 27.3, "four_week_move": 21.7, "twelve_week_move": 4.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.674683, "market_dynamics_buy_signal": false, "relative_strength": -13.038097, "fair_value_gap": -58.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 40.3361, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+27.3% over one week, +21.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 54, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 1}, {"label": "Market source", "count": 1}, {"label": "The Pharma Letter", "count": 1}, {"label": "StockInvest.us", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 4}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Market update", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "54/100 classification confidence."}, {"label": "Company focus", "value": "4", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+27.3% over one week, +21.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Kidney drug developer Vivoryon lines up June 11 Q1 2026 results"}], "updated_at": "2026-07-18T02:10:25.833981+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}